8-K: Travere Therapeutics' FILSPARI Receives Standard Marketing Authorization in Europe, Triggering $17.5 Million Milestone Payment

Travere Therapeutics and CSL Vifor announce European Commission approval converting conditional marketing approval to standard marketing authorization for FILSPARI in IgAN treatment, leading to a $17.5 million milestone payment.

Summary

• Travere Therapeutics and CSL Vifor announced that the European Commission has approved the conversion of the conditional marketing approval (CMA) into a standard marketing authorization (MA) for FILSPARI (sparsentan) for the treatment of adults with primary IgA nephropathy (IgAN).
• The standard marketing authorization is granted for all member states of the European Union, as well as in Iceland, Liechtenstein and Norway.
• The approval is based on positive confirmatory results from the pivotal Phase 3 PROTECT Study, demonstrating that FILSPARI significantly slowed kidney function decline over two years compared to irbesartan.
• As a result of the standard approval, Travere Therapeutics expects to receive a $17.5 million milestone payment from CSL Vifor.
• Travere Therapeutics remains eligible to receive additional milestone payments related to market access and sales-based achievements for FILSPARI.
• FILSPARI is the only dual endothelin angiotensin receptor antagonist (DEARA), a non-immunosuppressive therapy for the treatment of IgAN, approved in Europe, and is currently available in Germany, Austria and Switzerland.
• In the UK, the Medicines and Healthcare products Regulatory Agency (MHRA) converted the conditional FILSPARI approval to standard approval as of April 15, 2025.
• FILSPARI is indicated for the treatment of adults with primary IgAN with a urine protein excretion 1.0 g/day (or urine protein-to-creatinine ratio 0.75 g/g).

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the regulatory approval and associated milestone payment. While forward-looking statements include standard risk disclosures, the overall tone is optimistic.

Positives

• The European Commission's approval converts the conditional marketing approval to a standard marketing authorization for FILSPARI.
• Travere Therapeutics will receive a $17.5 million milestone payment from CSL Vifor.
• FILSPARI is available in Germany, Austria, and Switzerland.
• The UK MHRA has also granted standard approval for FILSPARI.

Risks

• The company faces risks and uncertainties associated with the regulatory review and approval process.
• There are risks and uncertainties associated with the continued commercial launch of FILSPARI in IgAN.
• The company faces risks and uncertainties related to its sNDA for FILSPARI in FSGS, including the timing and outcome thereof.
• The company faces risks associated with the timing and potential outcome of its and its partners clinical studies.
• There are risks related to the challenges of manufacturing scale-up.
• The company faces risks and uncertainties related to tariffs and the funding, staffing and prioritization of resources at government agencies including the FDA.
• The company faces the risk that it will be unable to raise additional funding that may be required to complete development of any or all of its product candidates, including as a result of macroeconomic conditions.
• There are uncertainties relating to patent protection and exclusivity periods and intellectual property rights of third parties.
• The company faces risks and uncertainties relating to competitive products, including current and potential future generic competition with certain of the company's products, and technological changes that may limit demand for the company's products.
• The company also faces additional risks associated with global and macroeconomic conditions, including health epidemics and pandemics, including risks related to potential disruptions to clinical trials, commercialization activity, supply chain, and manufacturing operations.

Future Outlook

The Company remains eligible to receive additional milestone payments related to market access and sales-based achievements for FILSPARI.

Industry Context

This approval strengthens FILSPARI's position in the IgAN treatment landscape in Europe, providing a non-immunosuppressive therapy option. It also highlights the ongoing efforts to address rare kidney diseases and the importance of regulatory approvals in expanding market access for novel treatments.

Comparison to Industry Standards

• FILSPARI's approval as a dual endothelin angiotensin receptor antagonist (DEARA) positions it uniquely compared to traditional treatments like ACE inhibitors or ARBs (e.g., irbesartan) that only target the renin-angiotensin system.
• Unlike immunosuppressants, FILSPARI offers a non-immunosuppressive approach, potentially appealing to patients and physicians seeking to avoid the side effects associated with immunosuppression.
• The $17.5 million milestone payment is a standard practice in the pharmaceutical industry, reflecting the achievement of a significant regulatory milestone.
• Comparable companies in the rare kidney disease space include Calliditas Therapeutics (developing therapies for IgAN) and Retrophin (now Travere Therapeutics), each pursuing different therapeutic strategies.

Stakeholder Impact

• Shareholders will benefit from the milestone payment and potential future revenue from FILSPARI sales.
• Patients with IgAN in Europe gain access to a new treatment option.
• The partnership between Travere Therapeutics and CSL Vifor is strengthened.

Next Steps

• Travere Therapeutics will receive the $17.5 million milestone payment from CSL Vifor.
• Travere Therapeutics will continue to pursue additional milestone payments related to market access and sales-based achievements for FILSPARI.
• The company will continue the commercial launch of FILSPARI in Europe.
• The company will await the outcome of its sNDA for FILSPARI in FSGS.

Key Dates

Keywords

FILSPARI, IgA nephropathy, IgAN, Travere Therapeutics, CSL Vifor, European Commission, Marketing Authorization, Milestone Payment, PROTECT Study, sparsentan